Nasdaq1mon
Quantum BioPharma Reports No Safety Concerns for Lucid-MS Following Successful Phase 1 Trial
Quantum BioPharma Ltd. has successfully completed its Phase 1 clinical trial of Lucid-21-302, also known as Lucid-MS, a novel compound aimed at treating multiple sclerosis (MS). A safety review ...
Nasdaq1mon
Quantum BioPharma Completes Phase 1 Trial Of Lucid-21-302 For Multiple Sclerosis Treatment
(RTTNews) - Quantum BioPharma Ltd. (QNTM) announced the completion of its Phase 1 clinical trial for Lucid-21-302 or Lucid-MS, an experimental drug designed to treat multiple sclerosis. The trial ...
Business Insider1mon
Quantum Group completes Phase 1 trial for Lucid-21-302
Quantum BioPharma announced that it has completed its trial entitled “A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and ...
A Lucid Air For $50,000 Could Be A Deal Too Good To Ignore
One of the most luxurious and compelling EVs in the market is dealing with shocking depreciation. Lucid is partly to blame ...
Yahoo Finance1mon
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today ...
Finanznachrichten1mon
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302
Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum ...